ArticleFrontiers in microbiology2025
Investigating the role of
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Review
- The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Obesity has become a major global health concern and is closely associated with imbalances in gut microbiota and chronic low-grade inflammation. Probiotics have been explored for their potential to prevent or alleviate obesity, especially in the case of Methods: Male C57BL/6J mice were fed a high-fat diet to induce obesity and then treated with either live or pasteurized Results: We observed that both forms of Akk11 provided protective benefits in obese mice, as evidenced by reductions in Lee's index and the area of white adipose tissue. In terms of intestinal health, both live and pasteurized Akk11 notably increased the number of goblet cells in the colon while also significantly improving mucosal integrity and enhancing the expression of tight junction proteins. Notably, 16S rRNA gene sequencing revealed that pasteurized Akk11 altered the gut microbiota composition, with significant differences in the dominant intestinal microbiota. The pasteurized Akk11 group showed a marked increase in the abundance of the Discussion: These findings indicated that both live and pasteurized Akk11 could serve as promising strategies for alleviating obesity linked to high-fat diets. This research supports the potential use of various
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.